Mohamad A Hussein

US Patent:

20110151494, Jun 23, 2011

Filed:

Jun 30, 2009

Appl. No.:

12/997210

Inventors:

John Matthew Koomen - Tampa FL, US
Elizabeth Renee Remily - Lutz FL, US
Kaaron Benson - Apollo Beach FL, US
Mohamad Hussein - Odessa FL, US

Assignee:

H. Lee Moffit Cancer & Research Institute - Tampa FL

International Classification:

C12Q 1/37
C07K 7/06
C07K 7/08
G01N 33/48

US Classification:

435 23, 530328, 530327, 530326, 436 86

Abstract:

The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods o f the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody. Thus, in one embodiment, both antibody and serum albumin and/or beta-2-microglobulin are detected and quantified using mass spectrometry and a diagnosis or prognosis made based on the results and levels detected.

US Patent:

20130260406, Oct 3, 2013

Filed:

May 30, 2013

Appl. No.:

13/905549

Inventors:

Elizabeth Renee Remily - Lutz FL, US
Kaaron Benson - Apollo Beach FL, US
Mohamad Hussein - Odessa FL, US

Assignee:

H. Lee Moffitt Cancer Center and Research Institute, Inc. - Tampa FL

International Classification:

G01N 33/68

US Classification:

435 23

Abstract:

The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods of the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody. Thus, in one embodiment, both antibody and serum albumin and/or beta-2-microglobulin are detected and quantified using mass spectrometry and a diagnosis or prognosis made based on the results and levels detected.

US Patent:

20160341742, Nov 24, 2016

Filed:

Aug 8, 2016

Appl. No.:

15/231467

Inventors:

- Tampa FL, US
Elizabeth Renee Remily - Lutz FL, US
Kaaron Benson - Apollo Beach FL, US
Mohamad Hussein - Odessa FL, US

International Classification:

G01N 33/68

Abstract:

The subject invention concerns methods and materials for diagnosing, monitoring the progress, and/or providing a prognosis for multiple myeloma and other conditions associated with antibody production in a person or animal. The methods of the invention utilize mass spectrometry for quantitative monitoring and detection of antibody produced by the plasma cells. The methods of the invention can be utilized for diagnosis, monitoring, and/or prognosis of multiple myeloma, monoclonal gammopathy, and other immunological or hematological conditions and disorders. In addition to detecting and quantifying antibody in a sample, other biological markers, such as serum albumin and/or beta-2-microglobulin, can also be detected and quantified using the present invention, and in combination with detection and quantification of antibody. Thus, in one embodiment, both antibody and serum albumin and/or beta-2-microglobulin are detected and quantified using mass spectrometry and a diagnosis or prognosis made based on the results and levels detected.